glp 1 clinical pearls Focus on GLP-1 Agonists in Type 2 Diabetes Mellitus GLP-1 Clinical Pharmacy Pearls

Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R

When grounded in biology, supported by robust evidence and aligned with patient and payer priorities, therapeutic versatility can translate into meaningful outcomes across multiple disease areas

In contrast to SCFA, bile acids are produced by the host

241 GLP-1(936) can directly act on pancreatic -cells to inhibit the secretion of glucagon

Ipamorelin has been extensively studied and shows excellent selectivity for GH release, minimal effects on other pituitary hormones, no major hunger boost (unlike GHRP-6), and favorable safety profile in clinical trials